Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

Core Insights - Cullinan Therapeutics is presenting new preclinical data for CLN-978, a bispecific T cell engager targeting autoimmune diseases, at the ACR Convergence 2025 [1][5] - CLN-978 has shown robust B cell depletion and T cell activation in patients with autoimmune diseases [2] - The drug demonstrated dose-dependent B cell depletion in nonhuman primates, indicating potential for significant clinical efficacy [3] - In murine models, CLN-978 treatment resulted in reduced circulating B cells and disease-modifying effects in systemic lupus erythematosus [4] Company Overview - Cullinan Therapeutics is focused on developing first- or best-in-class therapies for autoimmune diseases and cancer, leveraging expertise in T cell engagers [7] - The company is advancing global clinical programs for CLN-978 in rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus, with active trials in multiple countries [5][6] - CLN-978 is designed for high affinity binding to CD19, allowing it to target B cells effectively, including those with low CD19 levels [6]